[{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TB006","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TB006","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TB006","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TB006","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TB006","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TB006","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"TB006","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"TB006","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"TB006","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"TB006","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"},{"orgOrder":0,"company":"TrueBinding","sponsor":"TrueBinding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Chosource","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TrueBinding \/ TrueBinding","highestDevelopmentStatusID":"3","companyTruncated":"TrueBinding \/ TrueBinding"},{"orgOrder":0,"company":"TrueBinding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"TB006","moa":"Hepatitis A virus cellular receptor 2 (TIM3)","graph1":"Neurology","graph2":"Phase II","graph3":"TrueBinding","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TrueBinding \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TrueBinding \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by TrueBinding
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
